The U.S. Food and Drug Administration revised the Emergency Use Authorization, or EUA, for Evusheld to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, Evusheld is not currently authorized for use in the U.S. until further notice by the agency, the FDA announced. "Data show Evusheld is unlikely to be active against certain SARS-CoV-2 variants. According to the most recent CDC Nowcast data, these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants. Today’s action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time when fewer than 10% of circulating variants in the U.S. causing infection are susceptible to the product," the FDA stated in a notice posted to its website. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo receive EU approval for Enhertu
- Novartis downgraded to Neutral from Buy at Citi
- Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share